Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.41%430.050.0%$6120.58m
BNTXBioNTech SE -3.62%359.180.0%$1251.77m
NVAXNovavax, Inc. 0.11%237.5479.4%$944.01m
SNSSSunesis Pharmaceuticals, Inc. 2.23%8.710.7%$608.86m
AMGNAmgen, Inc. 0.93%219.381.4%$559.38m
REGNRegeneron Pharmaceuticals, Inc. -0.20%651.882.7%$494.43m
GILDGilead Sciences, Inc. 0.39%71.611.0%$434.34m
ILMNIllumina, Inc. -0.65%447.013.5%$405.38m
TECHBio-Techne Corp. 0.92%534.354.5%$355.95m
BIIBBiogen, Inc. 0.17%300.191.7%$306.30m
VRTXVertex Pharmaceuticals, Inc. 0.64%188.301.9%$241.59m
ISEEIVERIC bio, Inc. 1.59%16.620.0%$194.78m
BGNEBeiGene Ltd. 4.65%403.141.3%$186.17m
LIFEaTyr Pharma, Inc. 0.49%10.313.2%$144.19m
EXASEXACT Sciences Corp. 5.22%108.1518.1%$135.69m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.